Results

1–10 of 13 results for Robert L. Avery

OTX-TKI for the Treatment of Neovascular Age-related Macular Degeneration 12-Month Results From a US Clinical Trial
Robert L. Avery, MD
Annual Meeting Talks
2023
1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2025
Modulation of Macrophages and Complement Dysfunction in Nonexudative AMD Utilizing Novel Sialic Acid-Coated Nanoparticles
Robert L. Avery, MD
Updates from the Field
2024
Comparison of Hypochlorous Acid vs. Povidone Iodine Use Prior to Intravitreal Injection: A Randomized Prospective Trial Study
Robert L. Avery, MD
Annual Meeting Talks
2021
Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2021
Therapeutic Horizons for Dry AMD
Robert L. Avery, MD
Updates from the Field
2019
AMD Neovascular Expert Panel
Robert L. Avery, MD
Nizar S Abdelfattah, M.D.
Nancy M. Holekamp, MD, FASRS
Peter K. Kaiser, MD FASRS
Pravin U. Dugel, MD
Annual Meeting Talks
2016
Potential Safety Concerns of Bevacizumab for Retinopathy of Prematurity
Robert L. Avery, MD
Annual Meeting Talks
2016
My Practice is Worth WHAT? Equity Acquisition in the Retina World
Robert L. Avery, MD
Carl W. Baker, MD, FASRS
Michael S. Jacobson, MD
Reginald J. Sanders, MD, FASRS
Annual Meeting Talks
2018
Do Anti-VEGF Injections Affect the Development of Neovascular AMD in Fellow Eyes? A Meta-analysis of Clinical Trials
Robert L. Avery, MD
Annual Meeting Talks
2018